Interested in learning more about the role of artificial intelligence in rare disease drug discovery, clinical studies, phenotypic drug discovery, digital biomarkers and more? We recommend attending this BioNJ-hosted briefing session featuring Simone Manso, our Head of Neurofibromatosis Therapy Development.

The panel session (09:00-11:00 ET) will be moderated by Daniela Brunner, Ph.D.

Chief Innovation Officer of PsychoGenics and will cover many aspects of drug discovery including:

• AI-powered, patient-inspired treatments for rare diseases – Simone Manso, Head of Neurofibromatosis Therapy Development at Healx
• Application of multimodal data analytics for biomarker discovery and adaptive clinical trials – Magali Haas, CEO and President at Cohen Veterans Bioscience
• Augmented intelligence in drug development – Friso Postma, Senior Director & Head of Neurological Rare Diseases at BioXcel Therapeutics
• First-in-class, clinically-effective neuropsychiatric treatments – Emer Leahy, CEO and President at PsychoGenics

We’re looking forward to what’s set to be an insightful session. Will we see you there? If you aren’t attending but would like to learn more about our work, please contact us for more information.